GHRP-6
A growth hormone–releasing peptide studied in earlier clinical research; not FDA-approved.
What it is
GHRP-6 is a sibling of GHRP-2 — an early synthetic growth-hormone-releasing peptide acting on the ghrelin receptor, with pronounced appetite stimulation as its calling card.
Like the rest of the GHRP family it never became an approved drug, and its published human research is early-phase work from decades ago. It circulates today almost entirely through gray-market channels.
What researchers have actually studied it for
Growth-hormone release in early clinical research, with strong ghrelin-receptor-driven appetite effects.
How it works
The first hexapeptide of the GHRP series to see wide study: a ghrelin-receptor agonist releasing GH from the pituitary with the family's strongest reputation for hunger induction — a direct receptor effect, not a quirk.
Where it came from
Synthesized in the early 1980s from enkephalin-derivative research — the compound that effectively launched the secretagogue field and helped lead science to the ghrelin receptor itself. Its scientific importance is historical; its development ended without a drug.
What the research record actually contains
- Foundational early human pharmacology of GH release.
- Appetite-stimulation observations throughout the early literature.
- No controlled outcome trials in healthy adults, ever.
What's known about risks
Acute tolerability in old studies; hunger, water retention and mild hormonal spillover recur. Chronic-use safety: never characterized.
Where it stands legally
Unapproved; research-chemical market; prohibited in tested sport.
Worth asking a licensed provider
- 1.What outcome am I actually pursuing, and does any human data connect this compound to it?
- 2.Would appetite stimulation help or sabotage my plan?
- 3.What supervised alternatives exist with actual evidence?